AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27740724 — intervention group
Group type: COMPARATOR
Intervention: No dornase treatment
Number of subjects: 73
Study 27740724 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment costs
Number of subjects: 73
Study 27740724 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient stays
Number of subjects: 73
Study 27740724 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and clinical risk factors
Number of subjects: 73
Study 24037670 — intervention group
Group type: EXPERIMENTAL
Intervention: Peetrons grading and specific prognostic MRI parameters
Number of subjects: 25
Study 24037670 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic MRI parameters
Number of subjects: 25
Study 24037670 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific MRI parameters (distance from ischial tuberosity, extent, maximum cross-sectional area, volume of oedema)
Number of subjects: 25
Study 23385036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac
Number of subjects: 30
Study 23385036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20797750 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (DP)
Number of subjects: 20
Study 20797750 — intervention group
Group type: COMPARATOR
Intervention: Cardiac pacemakers
Number of subjects: 20
Study 18245069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fidelity model training
Number of subjects: 30
Study 18245069 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity model training
Number of subjects: 30
Study 20673545 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided treatment
Number of subjects: 429
Study 20673545 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 429
Study 20673545 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different treatment algorithms
Number of subjects: 429
Study 15607689 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 7
Study 15607689 — intervention group
Group type: COMPARATOR
Intervention: Saccharin (control)
Number of subjects: 7
Study 11785838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chemotherapy with m-BACOD (methotrexate, bleomycin, doxorubicin, vincristine, and dexamethasone)
Number of subjects: 0
Study 11785838 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose m-BACOD with sargramostim (GM-CSF)
Number of subjects: 0
Study 11785838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 0 or 1 adverse prognostic factors
Number of subjects: 0
Study 11785838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 3 or 4 adverse prognostic factors
Number of subjects: 0
Study 9611052 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic assay for Chlamydia
Number of subjects: 118
Study 9611052 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic assay for HSV 2 IgM
Number of subjects: 118
Study 9611052 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic assays for sexually transmitted diseases
Number of subjects: 118
Study 9611052 — intervention group
Group type: COMPARATOR
Intervention: Matched control group with normal cervical cytology
Number of subjects: 118
Study 8156313 — intervention group
Group type: EXPERIMENTAL
Intervention: Day patient care
Number of subjects: 20
Study 8156313 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 20
Study 3074595 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate 76%
Number of subjects: 48
Study 3074595 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 370
Number of subjects: 48
Study 30088567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Protraction Appliance (MPA)
Number of subjects: 39
Study 27163222 — intervention group
Group type: EXPERIMENTAL
Intervention: FFC-AC (Function-Focused Care for Acute Care)
Number of subjects: 89
Study 27163222 — intervention group
Group type: COMPARATOR
Intervention: FFC-EO (Function-Focused Care Education Only)
Number of subjects: 89
Study 25241181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (formula)
Number of subjects: 200
Study 25241181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 22033341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicle flap design
Number of subjects: 52
Study 22033341 — intervention group
Group type: COMPARATOR
Intervention: Buccal envelope flap
Number of subjects: 52
Study 20728707 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 150
Study 20728707 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg indomethacin
Number of subjects: 150
Study 20728707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 18383146 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0
Study 18383146 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16039733 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg orally twice daily for 4 doses
Number of subjects: 95
Study 16039733 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam 0.1 mcg/kg/min intravenously for a minimum of 8 h
Number of subjects: 95
Study 12667380 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA, 20 mg per day plus vitamin B(12) 1 mg, intramuscularly, per month for one year, then 20 mg two times a week plus 1 mg per three months for the next year)
Number of subjects: 216
Study 12667380 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural beta-carotene (N-betaC, 30 mg per day for first year, then 30 mg two times a week for the next)
Number of subjects: 216
Study 12667380 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic beta-carotene (S-betaC, administered as in N-betaC)
Number of subjects: 216
Study 12667380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 10382572 — intervention group
Group type: EXPERIMENTAL
Intervention: Test varnish containing 1% chlorhexidine and 1% thymol
Number of subjects: 20
Study 10382572 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (control) consisting of ethanol, ethylacetate and polyvinylbutyral
Number of subjects: 20
Study 10382572 — intervention group
Group type: EXPERIMENTAL
Intervention: Test varnish
Number of subjects: 20
Study 10382572 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (control)
Number of subjects: 20
Study 8694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol alone (200 micrograms administered vaginally every 12 hours)
Number of subjects: 68
Study 8694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol with laminaria (200 micrograms administered vaginally every 12 hours with intracervical placement of laminaria)
Number of subjects: 68
Study 8694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol alone
Number of subjects: 68
Study 8694046 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol with laminaria
Number of subjects: 68
Study 1805818 — intervention group
Group type: EXPERIMENTAL
Intervention: rubidazone (zorubicin) 200 mg/m2/d, days 1 to 4 plus cytarabine (Ara C) 200 mg/m2/d, days 1 to 7 (arm A)
Number of subjects: 39
Study 1805818 — intervention group
Group type: EXPERIMENTAL
Intervention: amsacrine (Amsa) 150 mg/m2/d, days 1 to 4 plus Ara C 200 mg/m2/d, days 1 to 7 (arm B)
Number of subjects: 39
Study 1805818 — intervention group
Group type: EXPERIMENTAL
Intervention: arm A (rubidazone + Ara C)
Number of subjects: 39
Study 1805818 — intervention group
Group type: EXPERIMENTAL
Intervention: arm B (amsacrine + Ara C)
Number of subjects: 39
Study 6460974 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (1 g, intravenously)
Number of subjects: 10
Study 6460974 — intervention group
Group type: COMPARATOR
Intervention: ampicillin (1 g, intravenously)
Number of subjects: 10
Study 6460974 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (1 g, intramuscularly)
Number of subjects: 10
Study 6460974 — intervention group
Group type: COMPARATOR
Intervention: ampicillin (1 g, intramuscularly)
Number of subjects: 10
Study 6460974 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (1 g, intramuscularly) with probenecid (1 g, orally)
Number of subjects: 10
Study 29976648 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 30
Study 29976648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27938960 — intervention group
Group type: EXPERIMENTAL
Intervention: narrated white board animation (nWBA)
Number of subjects: 78
Study 27938960 — intervention group
Group type: COMPARATOR
Intervention: standard physician‐patient interaction
Number of subjects: 78
Study 27938960 — intervention group
Group type: EXPERIMENTAL
Intervention: both standard and nWBA consent
Number of subjects: 78
Study 25115748 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy alone or combined with contingency management
Number of subjects: 23
Study 25115748 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy comparison individuals)
Number of subjects: 23
Study 22837058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,470 nm diode laser (contact mode, 15 W power)
Number of subjects: 21
Study 22837058 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide laser (12 W power)
Number of subjects: 21
Study 22837058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 21
Study 21188919 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 24
Study 21188919 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX+NaF+ZnCl2
Number of subjects: 24
Study 18534821 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 246
Study 18534821 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 246
Study 18534821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 246
Study 18534821 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 246
Study 18534821 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 246
Study 18534821 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine vs. Olanzapine
Number of subjects: 246
Study 18534821 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine vs. Quetiapine
Number of subjects: 246
Study 16313121 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenggan Recipe (ZGR)
Number of subjects: 64
Study 15557529 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 0
Study 15557529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11789240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium polyglycoside (TP)
Number of subjects: 43
Study 11789240 — intervention group
Group type: COMPARATOR
Intervention: Adrenal corticosteroid
Number of subjects: 43
Study 9586486 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAGD occlusal adjustments to shorten disclusion time to less than .5 seconds per mandibular excursion (10 subjects)
Number of subjects: 25
Study 9586486 — intervention group
Group type: COMPARATOR
Intervention: Mock ICAGD with tooth polishing (8 subjects)
Number of subjects: 25
Study 9586486 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 25
Study 8456754 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 1387
Study 3510612 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride (0.5%)
Number of subjects: 29
Study 3510612 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate (0.5%)
Number of subjects: 29
Study 30183208 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (10 μg, once daily) and calcium dobesilate (0.5 g, 3 times daily)
Number of subjects: 120
Study 30183208 — intervention group
Group type: COMPARATOR
Intervention: Alprostadil (10 μg, once daily)
Number of subjects: 120
Study 26717493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (20-60 or 80-120 mg/day)
Number of subjects: 639
Study 26717493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy (20-120 mg/day)
Number of subjects: 639
Study 23690000 — intervention group
Group type: EXPERIMENTAL
Intervention: High-reward pictures
Number of subjects: 0
Study 23690000 — intervention group
Group type: COMPARATOR
Intervention: Low-reward pictures
Number of subjects: 0
Study 23690000 — intervention group
Group type: COMPARATOR
Intervention: Immediate recognition
Number of subjects: 0
Study 23690000 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour study-test delay
Number of subjects: 0
Study 23055489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine precursor levodopa
Number of subjects: 0
Study 23055489 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20542272 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 72
Study 20542272 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 72
Study 18446716 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (6.0 g daily for 12 months) plus low-protein diet and RAS blocker therapy (group A)
Number of subjects: 28
Study 18446716 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (group B, no AST-120)
Number of subjects: 28
Study 16164489 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (64 mmol/day intravenously)
Number of subjects: 94
Study 16164489 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 94
Study 14674665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg twice daily, clarithromycin 250 mg twice daily, metronidazole 500 mg twice daily for 4 days (n = 63)
Number of subjects: 128
Study 14674665 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg twice daily, clarithromycin 250 mg twice daily, metronidazole 500 mg twice daily for 7 days (n = 65)
Number of subjects: 128
Study 10223594 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate (IMM) zidovudine therapy
Number of subjects: 297
Study 10223594 — intervention group
Group type: COMPARATOR
Intervention: Deferred (DEF) zidovudine therapy
Number of subjects: 297
Study 7884546 — intervention group
Group type: EXPERIMENTAL
Intervention: Soycreme administration
Number of subjects: 36
Study 7884546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no soycreme)
Number of subjects: 36
Study 2203249 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) injections (0.1 mg/kg ideal body weight every other day)
Number of subjects: 8
Study 2203249 — intervention group
Group type: COMPARATOR
Intervention: Vehicle injections (control)
Number of subjects: 8
Study 2203249 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) injections
Number of subjects: 8
Study 213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy with postoperative irradiation
Number of subjects: 1539
Study 213374 — intervention group
Group type: COMPARATOR
Intervention: Total mastectomy without postoperative irradiation
Number of subjects: 1539
Study 213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 1539
Study 213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment overall (including all types)
Number of subjects: 1539
Study 213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis
Number of subjects: 1539
Study 213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size < 5 cm
Number of subjects: 1539
Study 31228197 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based social-cognitive intervention (4 weekly 1-hr face-to-face sessions)
Number of subjects: 264
Study 31228197 — intervention group
Group type: COMPARATOR
Intervention: Active control group (parallel sessions targeting physical activity)
Number of subjects: 264
Study 29150995 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous PTA
Number of subjects: 115
Study 29150995 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 115
Study 27228110 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching (mean 3.73 hours/day in the first year, 3.43 hours/day thereafter)
Number of subjects: 109
Study 27228110 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 109
Study 23944980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral paramedian (double needle) technique
Number of subjects: 60
Study 23944980 — intervention group
Group type: COMPARATOR
Intervention: Unilateral paramedian (single needle) technique
Number of subjects: 60
Study 23944980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study 21404089 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow up-titration of paroxetine (arm A)
Number of subjects: 30
Study 21404089 — intervention group
Group type: COMPARATOR
Intervention: Standard up-titration of paroxetine (arm B)
Number of subjects: 30
Study 20061165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized liposomal amphotericin B (n-LAB)
Number of subjects: 104
Study 20061165 — intervention group
Group type: COMPARATOR
Intervention: Nebulized amphotericin B deoxycholate (n-ABD)
Number of subjects: 104
Study 18545177 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic stretching
Number of subjects: 11
Study 18545177 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 11
Study 18545177 — intervention group
Group type: COMPARATOR
Intervention: Dynamic stretching
Number of subjects: 11
Study 18545177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined static and dynamic stretching
Number of subjects: 11
Study 18545177 — intervention group
Group type: COMPARATOR
Intervention: No stretching
Number of subjects: 11
Study 15925125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 15925125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14601158 — intervention group
Group type: EXPERIMENTAL
Intervention: Designed data RCTs
Number of subjects: 0
Study 14601158 — intervention group
Group type: COMPARATOR
Intervention: Routine data RCTs
Number of subjects: 0
Study 10523736 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-inducing situation
Number of subjects: 52
Study 10523736 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anger-inducing situation
Number of subjects: 52
Study 10523736 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study 7734295 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cyclophosphamide, epirubicin and fluorouracil
Number of subjects: 81
Study 7734295 — intervention group
Group type: COMPARATOR
Intervention: DNA ploidy
Number of subjects: 81
Study 2281427 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled micronised gentamicin powder (180 mg)
Number of subjects: 40
Study 2281427 — intervention group
Group type: COMPARATOR
Intervention: Nebulised gentamicin solution (160 mg)
Number of subjects: 40
Study 7435264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg b.i.d.
Number of subjects: 111
Study 7435264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 6219912 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g Meclocillin (single dose)
Number of subjects: 100
Study 6219912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Meclocillin)
Number of subjects: 100
Study 30401608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU monthly for 24 months)
Number of subjects: 413
Study 30401608 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining vitamin D sufficiency
Number of subjects: 413
Study 30401608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 413
Study 29614897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) plus dietary counselling (DC)
Number of subjects: 255
Study 29614897 — intervention group
Group type: COMPARATOR
Intervention: Control (dietary counselling alone)
Number of subjects: 255
Study 26864092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 6595
Study 26864092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study 25238785 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of corticosteroids
Number of subjects: 0
Study 25238785 — intervention group
Group type: COMPARATOR
Intervention: Delayed antibiotic prescription or no antibiotic prescription (control)
Number of subjects: 0
Study 23185303 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV-7)
Number of subjects: 328
Study 23185303 — intervention group
Group type: COMPARATOR
Intervention: Control villages (infants aged 2-30 months receiving Meningococcal C conjugate vaccine)
Number of subjects: 328
Study 20098137 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (basal 12 ml/h, bolus 4 ml)
Number of subjects: 50
Study 20098137 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine (basal 3 ml/h, bolus 1 ml)
Number of subjects: 50
Study 20098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.1% and 0.4% ropivacaine)
Number of subjects: 50
Study 17363337 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg) in patients with panic disorder
Number of subjects: 30
Study 17363337 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg) in healthy controls
Number of subjects: 30
Study 17363337 — intervention group
Group type: COMPARATOR
Intervention: Placebo in healthy controls
Number of subjects: 30
Study 16278615 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of estradiol plus 2.0 mg of drospirenone (DRSP/E(2))
Number of subjects: 1147
Study 16278615 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg of estradiol alone (E(2) monotherapy)
Number of subjects: 1147
Study 16278615 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone and estradiol combinations
Number of subjects: 1147
Study 16278615 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1147
Study 16278615 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone combined with estradiol
Number of subjects: 1147
Study 12086758 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 1034